Skip to main content

Latest Special Issue

  • Clinical Trials to Clinical Practice: GI Cancer Edition

    OPDIVO® (nivolumab) in Combination with Chemotherapy as First-Line Therapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma as well as Unresectable Advanced or Metastatic Esophageal Squamous-Cell Carcinoma: Results from Checkmate 649 and Checkmate 648

Special Issues Archive


Clinical Trials to Clinical Practice: GI Cancer Edition

Best Practices: Education for Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors

2023 Oncology Guide to Patient Support Services

2022 Year in Review: Multiple Myeloma

2022 Year in Review: Cholangiocarcinoma

Faculty Perspectives: Optimizing Clinical Outcomes and Value-Based Management in Multiple Myeloma—The Role of Isatuximab

Current Approach to the Disease Journey of Patients with Relapsed or Refractory Follicular Lymphoma: Focus on the Key Manifestations, Risk Stratification, and Management Patterns

Best Practices: Immune-Related Adverse Event Management in Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors

Best Practices: Biomarkers and Treatment Selection in the Management of Advanced NSCLC

2022 Midyear Review: Non–Small-Cell Lung Cancer

Faculty Perspectives: The Evolving Clinical and Pharmacoeconomic Impact of Isatuximab in Multiple Myeloma Management

ASK THE EXPERT: First-Line OPDIVO® (nivolumab) in Combination with Chemotherapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma

Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy

2021 Year in Review: Advances in Dual Immunotherapy Cancer Treatments

2021 Year in Review: Advances in Dual Immunotherapy Cancer Treatments

2022 Oncology Biosimilar Guide to Patient Support Services

2022 Breast Cancer Guide to Patient Support Services

2022 Oncology Guide to Patient Support Services

 

Back to Top